Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

6.29
-0.5450-7.97%
Post-market: 6.380.0900+1.43%19:59 EDT
Volume:8.36M
Turnover:53.59M
Market Cap:365.69M
PE:-2.55
High:7.08
Open:6.81
Low:6.01
Close:6.84
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.38
T/O Rate:18.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:1.49
PE(LYR):-2.78

Loading ...

Capricor Therapeutics Inc - No Revenue Recognized for Q1 2026 or Q1 2025

THOMSON REUTERS
·
May 13

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 13

Capricor Therapeutics: Available Cash, Cash Equivalents, Marketable Securities Sufficient to Cover Expenses & Capital Requirements Through Q4 2027

THOMSON REUTERS
·
May 13

Analysts Offer Insights on Healthcare Companies: ImageneBio (IMA) and Capricor Therapeutics (CAPR)

TIPRANKS
·
May 11

Capricor files suit against NS Pharma over Deramiocel distribution deal

TIPRANKS
·
May 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Capricor Therapeutics (CAPR), Enovis (ENOV) and Progyny (PGNY)

TIPRANKS
·
May 09

Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

Benzinga
·
May 08

H.C. Wainwright Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 08

Capricor sues Nippon Shinyaku over US distribution rights for CAP-1002

Reuters
·
May 08

Capricor Therapeutics Inc - Alleges Ns Pharma Failed to Prepare for Deramiocel Launch and Breached Agreement - SEC Filing

THOMSON REUTERS
·
May 08

Capricor Therapeutics Inc - Files Lawsuit and Seeks Preliminary Injunction in New Jersey Court on May 7, 2026 - SEC Filing

THOMSON REUTERS
·
May 08

Earning Preview: Capricor Therapeutics this quarter’s revenue is expected to decrease by 100%, and institutional views are bullish

Earnings Agent
·
May 06

Capricor CFO Anthony Bergmann disposes of 25,000 shares worth $792,540

Reuters
·
May 05

Capricor EVP, General Counsel Karen Krasney disposes 25,000 shares for $792,548‬

Reuters
·
May 05

Capricor Therapeutics schedules first-quarter 2026 financial results conference call and webcast

Reuters
·
May 05

Press Release: Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Dow Jones
·
May 05

Capricor Therapeutics (CAPR) Is Down 12.4% After New HOPE-3 Deramiocel Phase 3 Data Release - What's Changed

Simply Wall St.
·
May 03

Capricor reports Phase 3 HOPE-3 trial results for Deramiocel in Duchenne muscular dystrophy

Reuters
·
Apr 22

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire
·
Apr 22

Capricor Therapeutics (CAPR) Gets a Buy from Roth MKM

TIPRANKS
·
Apr 15